LEPTOMENINGEAL METASTASES
Clinical trials for LEPTOMENINGEAL METASTASES explained in plain language.
Never miss a new study
Get alerted when new LEPTOMENINGEAL METASTASES trials appear
Sign up with your email to follow new studies for LEPTOMENINGEAL METASTASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an old drug tame cancer in the spinal fluid? new trial aims to find out
Disease control Recruiting nowThis early-phase trial tests whether deferoxamine, a drug given directly into the spinal fluid, is safe for people with leptomeningeal metastases—cancer that has spread to the lining of the brain and spinal cord. Researchers will test different doses in 35 adults with solid tumor…
Matched conditions: LEPTOMENINGEAL METASTASES
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug zorifertinib aims to fight lung cancer in the brain
Disease control Recruiting nowThis study is testing a drug called zorifertinib as the first treatment for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has spread to the brain or spinal cord. The trial will enroll 800 participants and compare zorifertinib to othe…
Matched conditions: LEPTOMENINGEAL METASTASES
Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for deadliest breast cancer complication: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs—sacituzumab govitecan (given through a vein) and pemetrexed (given into the spinal fluid)—for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). This condition…
Matched conditions: LEPTOMENINGEAL METASTASES
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC